CD276 Protein (CD276) (AA 29-245) (Fc Tag)
-
- Target Alle CD276 Proteine anzeigen
- CD276
- Protein-Typ
- Recombinant
- Proteineigenschaft
- AA 29-245
-
Spezies
- Human
-
Quelle
- CHO Cells
- Aufreinigungstag / Konjugat
- Dieses CD276 Protein ist gelabelt mit Fc Tag.
- Verwendungszweck
- CD276 [B7-H3] (human):Fc (human) (rec.)
- Spezifität
- The extracellular domain of human CD276 [B7-H3] (aa 29-245) is fused to the N-terminus of the Fc region of human IgG1.
- Produktmerkmale
- Protein. The extracellular domain of human CD276 [B7-H3] (aa 29-245) is fused to the N-terminus of the Fc region of human IgG1. Source: CHO cells. Endotoxin content: <0.06EU/μg protein (LAL test, Lonza). Lyophilized from 0.2μm-filtered solution in PBS. Purity: >98 % (SDS-PAGE). CD276 (B7-H3) is a member of the B7/CD28 superfamily of costimulatory molecules serving as an accessory modulator of T cell response. B7 family molecules, which are expressed on antigen-presenting cells and display extracellular regions containing immunoglobulin (Ig) variable (V)- and constant (C)-like domains, are known to modulate T cell receptor (TCR)-mediated T cell activation by providing co-signals that are either stimulatory or inhibitory. B7-H3 provides a stimulatory signal to T cells. However, recent studies suggest a negative regulatory role for B7-H3 in T cell responses. B7-H3 inhibited T cell proliferation mediated by antibody to T cell receptor or allogeneic antigen-presenting cells. B7-H3 is a negative regulator that preferentially affects T(H)1 responses. B7-H3 may play an important role in muscle-immune interactions, providing further evidence of the active role of muscle cells in local immunoregulatory processes. Recently, B7-H3 expression has also been found in a variety of different human cancers, including prostate cancer, clear cell renal cell carcinoma (ccRCC), non-small-cell lung cancer (NSCLC), pancreatic cancer, gastric cancer, ovarian cancer, colorectal cancer (CRC) and urothelial cell carcinoma. B7-H3 was expressed in some human cancers and correlated with poor outcome of cancer patients.
- Reinheit
- >98 % (SDS-PAGE)
- Endotoxin-Niveau
- <0.06EU/μg protein (LAL test, Lonza).
- Top Product
- Discover our top product CD276 Protein
-
-
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Lyophilized
- Konzentration
- Lot specific
- Buffer
- Lyophilized from 0.2μm-filtered solution in PBS.
- Handhabung
- Avoid freeze/thaw cycles.
- Lagerung
- 4 °C,-20 °C
- Informationen zur Lagerung
-
Short Term Storage: +4°C
Long Term Storage: -20°C
Use & Stability: Stable for at least 1 year after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C.
-
- Target
- CD276
- Andere Bezeichnung
- CD276 [B7-H3] (CD276 Produkte)
- Synonyme
- sc:d0645 Protein, zgc:158279 Protein, 6030411F23Rik Protein, AU016588 Protein, B7RP-2 Protein, B7h3 Protein, B7H3 Protein, 4Ig-B7-H3 Protein, B7-H3 Protein, CD276 molecule Protein, CD276 molecule S homeolog Protein, CD276 antigen Protein, Cd276 molecule Protein, CD276 Protein, cd276.S Protein, cd276 Protein, Cd276 Protein
- Hintergrund
-
Alternate Names/Synonyms: B7-H3
Product Description: CD276 (B7-H3) is a member of the B7/CD28 superfamily of costimulatory molecules serving as an accessory modulator of T cell response. B7 family molecules, which are expressed on antigen-presenting cells and display extracellular regions containing immunoglobulin (Ig) variable (V)- and constant (C)-like domains, are known to modulate T cell receptor (TCR)-mediated T cell activation by providing co-signals that are either stimulatory or inhibitory. B7-H3 provides a stimulatory signal to T cells. However, recent studies suggest a negative regulatory role for B7-H3 in T cell responses. B7-H3 inhibited T cell proliferation mediated by antibody to T cell receptor or allogeneic antigen-presenting cells. B7-H3 is a negative regulator that preferentially affects T(H)1 responses. B7-H3 may play an important role in muscle-immune interactions, providing further evidence of the active role of muscle cells in local immunoregulatory processes. Recently, B7-H3 expression has also been found in a variety of different human cancers, including prostate cancer, clear cell renal cell carcinoma (ccRCC), non-small-cell lung cancer (NSCLC), pancreatic cancer, gastric cancer, ovarian cancer, colorectal cancer (CRC) and urothelial cell carcinoma. B7-H3 was expressed in some human cancers and correlated with poor outcome of cancer patients.
- NCBI Accession
- NP_079516
- Pathways
- Cancer Immune Checkpoints
-